Time-staggered delivery of docetaxel and H1-S6A,F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting

Journal of Controlled Release

Volumn 232, Issue , 2016, Pages 62-74

  Li, Lian ^a   Sun, Wei ^a   Zhang, Zhirong ^a   Huang, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Combinatory therapy; HPMA copolymers; Nuclear delivery; Sequential treatment; Synergistic effect

Indexed keywords

CELL MEMBRANES; CHEMOTHERAPY; PEPTIDES;

COMBINATORY THERAPY; HPMA COPOLYMERS; NUCLEAR DELIVERY; SEQUENTIAL TREATMENTS; SYNERGISTIC EFFECT;

TUMORS;

ANTINEOPLASTIC AGENT; DOCETAXEL; H1 S6A F8A PEPTIDE; MYC PROTEIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; PEPTIDE; POLYMETHACRYLIC ACID DERIVATIVE; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG POTENTIATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE DAMAGE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERINE CERVIX CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; FEMALE; HELA CELLS; HUMANS; MICE, NUDE; NEOPLASMS; PEPTIDES; POLYMETHACRYLIC ACIDS; PROTO-ONCOGENE PROTEINS C-MYC; TAXOIDS; TUMOR BURDEN;

EID: 84964324549     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.04.021     Document Type: Article

References (55)

1. C.V. Dang MYC on the path to cancer Cell 149 2012 22 35
2. M. Jain, C. Arvanitis, K. Chu, W. Dewey, E. Leonhardt, M. Trinh, C.D. Sundberg, J.M. Bishop, and D.W. Felsher Sustained loss of a neoplastic phenotype by brief inactivation of MYC Science 297 2002 102 104
3. M. Toyoshima, H.L. Howie, M. Imakura, R.M. Walsh, J.E. Annis, A.N. Chang, J. Frazier, B.N. Chau, A. Loboda, P.S. Linsley, M.A. Cleary, J.R. Park, and C. Grandori Functional genomics identifies therapeutic targets for MYC-driven cancer Proc. Natl. Acad. Sci. U. S. A. 109 2012 9545 9550
4. Y. Zhang, L. Peng, R.J. Mumper, and L. Huang Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy Biomaterials 34 2013 8459 8468
5. D. Pan, B. Kim, G. Hu, D.S. Gupta, A. Senpan, X. Yang, A. Schmieder, C. Swain, S.A. Wickline, M.H. Tomasson, and G.M. Lanza A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy Nanomedicine (London) 10 2015 241 251
6. G.L. Bidwell 3rd, A.N. Davis, and D. Raucher Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides J. Control. Release 135 2009 2 10
7. J. Zhong, L. Li, X. Zhu, S. Guan, Q. Yang, Z. Zhou, Z. Zhang, and Y. Huang A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery Biomaterials 65 2015 43 55
8. S.D. Perrault, C. Walkey, T. Jennings, H.C. Fischer, and W.C. Chan Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9 2009 1909 1915
9. Y. Fan, C. Li, H. Cao, F. Li, and D. Chen The intranuclear release of a potential anticancer drug from small nanoparticles that are derived from intracellular dissociation of large nanoparticles Biomaterials 33 2012 4220 4228
10. Q. He, and J. Shi MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition Adv. Mater. 26 2014 391 411
11. A.G. Tkachenko, H. Xie, D. Coleman, W. Glomm, J. Ryan, M.F. Anderson, S. Franzen, and D.L. Feldheim Multifunctional gold nanoparticle-peptide complexes for nuclear targeting J. Am. Chem. Soc. 125 2003 4700 4701
12. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572
13. D. Sarko, B. Beijer, R. Garcia Boy, E.M. Nothelfer, K. Leotta, M. Eisenhut, A. Altmann, U. Haberkorn, and W. Mier The pharmacokinetics of cell-penetrating peptides Mol. Pharm. 7 2010 2224 2231
14. R. Zhang, K. Luo, J. Yang, M. Sima, Y. Sun, M.M. Janat-Amsbury, and J. Kopecek Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel J. Control. Release 166 2013 66 74
15. H. Pan, M. Sima, S.C. Miller, P. Kopeckova, J. Yang, and J. Kopecek Efficiency of high molecular weight backbone degradable HPMA copolymer-prostaglandin E1 conjugate in promotion of bone formation in ovariectomized rats Biomaterials 34 2013 6528 6538
16. R. Zhang, J. Yang, M. Sima, Y. Zhou, and J. Kopecek Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates Proc. Natl. Acad. Sci. U. S. A. 111 2014 12181 12186
17. S. Huo, S. Jin, X. Ma, X. Xue, K. Yang, A. Kumar, P.C. Wang, J. Zhang, Z. Hu, and X.J. Liang Ultrasmall gold nanoparticles as carriers for nucleus-based gene therapy due to size-dependent nuclear entry ACS Nano 8 2014 5852 5862
18. L. Li, W. Sun, J. Zhong, Q. Yang, X. Zhu, Z. Zhou, Z.R. Zhang, and Y. Huang Multistage nanovehicle delivery system based on stepwise size reduction and charge reversal for programmed nuclear targeting of systemically administered anticancer drugs Adv. Funct. Mater. 25 2015 4101 4113
19. J. Yang, and J. Kopecek Design of smart HPMA copolymer-based nanomedicines J. Control. Release 2015
20. J. Callahan, P. Kopeckov, and J. Kopecek Intracellular trafficking and subcellular distribution of a large array of HPMA copolymers Biomacromolecules 10 2009 1704 1714
21. Y. Shamay, L. Adar, G. Ashkenasy, and A. David Light induced drug delivery into cancer cells Biomaterials 32 2011 1377 1386
22. K. Remaut, N. Symens, B. Lucas, J. Demeester, and S.C. De Smedt Cell division responsive peptides for optimized plasmid DNA delivery: the mitotic window of opportunity? J. Control. Release 179 2014 1 9
23. J.A. Kim, C. Aberg, A. Salvati, and K.A. Dawson Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population Nat. Nanotechnol. 7 2012 62 68
24. H. Gao, G. Hu, Q. Zhang, S. Zhang, X. Jiang, and Q. He Pretreatment with chemotherapeutics for enhanced nanoparticles accumulation in tumor: the potential role of G2 cycle retention effect Sci. Rep. 4 2014 4492
25. E. Manchado, M. Guillamot, and M. Malumbres Killing cells by targeting mitosis Cell Death Differ. 19 2012 369 377
26. K.S. Chan, C.G. Koh, and H.Y. Li Mitosis-targeted anti-cancer therapies: where they stand Cell Death Dis. 3 2012 e411
27. G.L. Bidwell 3rd, and D. Raucher Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy Mol. Cancer Ther. 4 2005 1076 1085
28. S.K. Nair, and S.K. Burley X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors Cell 112 2003 193 205
29. T. Berg, S.B. Cohen, J. Desharnais, C. Sonderegger, D.J. Maslyar, J. Goldberg, D.L. Boger, and P.K. Vogt Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts Proc. Natl. Acad. Sci. U. S. A. 99 2002 3830 3835
30. M. Sui, W. Liu, and Y. Shen Nuclear drug delivery for cancer chemotherapy J. Control. Release 155 2011 227 236
31. L. Li, Q. Yang, Z. Zhou, J. Zhong, and Y. Huang Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting Biomaterials 35 2014 5171 5187
32. Q. Yang, Y. Yang, L. Li, W. Sun, X. Zhu, and Y. Huang Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer ACS Appl. Mater. Interfaces 7 2015 6661 6673
33. T. Etrych, M. Sirova, L. Starovoytova, B. Rihova, and K. Ulbrich HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release Mol. Pharm. 7 2010 1015 1026
34. M. Raoof, Y. Mackeyev, M.A. Cheney, L.J. Wilson, and S.A. Curley Internalization of C60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex Biomaterials 33 2012 2952 2960
35. G. Grandinetti, and T.M. Reineke Exploring the mechanism of plasmid DNA nuclear internalization with polymer-based vehicles Mol. Pharm. 9 2012 2256 2267
36. J. Zhang, L. Miao, S. Guo, Y. Zhang, L. Zhang, A. Satterlee, W.Y. Kim, and L. Huang Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model J. Control. Release 182 2014 90 96
37. J. Kopecek Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Deliv. Rev. 65 2013 49 59
38. J. Kopecek, and P. Kopeckova HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2010 122 149
39. H. Meng, M. Wang, H. Liu, X. Liu, A. Situ, B. Wu, Z. Ji, C.H. Chang, and A.E. Nel Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice ACS Nano 9 2015 3540 3557
40. D.D. Von Hoff, R.K. Ramanathan, M.J. Borad, D.A. Laheru, L.S. Smith, T.E. Wood, R.L. Korn, N. Desai, V. Trieu, J.L. Iglesias, H. Zhang, P. Soon-Shiong, T. Shi, N.V. Rajeshkumar, A. Maitra, and M. Hidalgo Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial J. Clin. Oncol. 29 2011 4548 4554
41. J.R. Kroep, G. Giaccone, C. Tolis, D.A. Voorn, W.J. Loves, C.J. Groeningen, H.M. Pinedo, and G.J. Peters Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines Br. J. Cancer 83 2000 1069 1076
42. C. Oliveras-Ferraros, A. Vazquez-Martin, R. Colomer, R. De Llorens, J. Brunet, and J.A. Menendez Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling Int. J. Oncol. 32 2008 113 120
43. M. Sui, X. Xiong, A.S. Kraft, and W. Fan Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis Cancer Biol. Ther. 5 2006 1015 1021
44. H. Maeda Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity Adv. Drug Deliv. Rev. 91 2015 3 6
45. Y. Yang, Z. Zhou, S. He, T. Fan, Y. Jin, X. Zhu, C. Chen, Z.R. Zhang, and Y. Huang Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates Biomaterials 33 2012 2260 2271
46. H. Cho, and G.S. Kwon Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging ACS Nano 5 2011 8721 8729
47. J. Wang, Z. Lu, J. Wang, M. Cui, B.Z. Yeung, D.J. Cole, M.G. Wientjes, and J.L. Au Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors J. Control. Release 216 2015 103 110
48. D.C. Park, J.H. Kim, Y.O. Lew, D.H. Kim, and S.E. Namkoong Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer Gynecol. Oncol. 92 2004 59 63
49. B. Coudert, M. Asselain, M. Campone, J.P. Spielmann, F. Machiels, D. Penault-Llorca, C. Serin, G. Levy, J.L. Romieu, H. Canon, G. Orfeuvre, T. Piot, G. Petit, B. Jerusalem, C. Audhuy, M. Veyret, J.C. Beauduin, A.L. Eymard, H. Martin, and Roche, U.B. Group Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial Oncologist 17 2012 900 909
50. K.K. Frese, A. Neesse, N. Cook, T.E. Bapiro, M.P. Lolkema, D.I. Jodrell, and D.A. Tuveson nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer Cancer Discov. 2 2012 260 269
51. T. Minko, P. Kopeckova, and J. Kopecek Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line J. Control. Release 59 1999 133 148
52. T. Minko HPMA copolymers for modulating cellular signaling and overcoming multidrug resistance Adv. Drug Deliv. Rev. 62 2010 192 202
53. R.C. Van Waardenburg, J. Prins, C. Meijer, D.R. Uges, E.G. De Vries, and N.H. Mulder Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines Anticancer Res. 16 1996 1963 1970
54. D.C. Knapp, J.E. Mata, M.T. Reddy, G.R. Devi, and P.L. Iversen Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model Anticancer Drugs 14 2003 39 47
55. H.K. Seo, K.O. Ahn, N.R. Jung, J.S. Shin, W.S. Park, K.H. Lee, S.J. Lee, and K.C. Jeong Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer Oncotarget 5 2014 326 337